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Introduction
Multiple endocrine neoplasia type 2A (MEN2A) is an autosomal dominant disorder associated 
with the occurrence of medullary thyroid carcinoma (MTC), phaeochromocytoma and 
parathyroid hyperplasia. The penetrance is almost 100% for MTC while approximately 
50% and 30% of patients will develop subsequent phaeochromocytomas and 
hyperparathyroidism, respectively.1-4
 Medullary thyroid carcinoma remains a major cause of death in MEN2A patients.5 
Before the introduction of genetic screening for the RET proto-oncogene, the diagnosis 
was usually delayed and led to frequent presence of nodal and distant metastases on 
presentation. Cancer-related mortality occurred in up to 15 to 20% of these patients.6,7 
Moreover, biochemical surveillance based on stimulated calcitonin for early diagnosis was 
associated with false-negative and false-positive results. In addition, the test was unpleasant 
and troublesome and needed to be repeated regularly for all at-risk patients. With the 
	 Objective	 To evaluate the impact of genetic testing in the management of 
familial multiple endocrine neoplasia 2A patients.
	 Design	 Retrospective study.
	 Setting	 University teaching hospital, Hong Kong.
	 Patients	 Twenty-two patients from eight multiple endocrine neoplasia 
2A families underwent prophylactic total thyroidectomy based 
on a positive RET mutation genetic testing. All mutations 
were located at codon 634 of exon 11. Nineteen patients had 
preoperative basal serum calcitonin measured, and the 12 with 
normal levels had pentagastrin stimulation tests. Preoperative 
thyroid ultrasound examination was performed for 17 patients.
	 Results	 There were 13 females and 9 males with a median age of 25.1 
(range, 6.1-71.9) years. Histopathology revealed medullary 
thyroid carcinoma in 17 (77%), C-cell hyperplasia in four (18%), 
and normal pathology in one (5%) of the patients. Five patients 
with either C-cell hyperplasia or normal pathology were among 
the youngest (age range, 6-9 years). The youngest patient with 
medullary thyroid carcinoma was nearly 9 years old. The median 
size of medullary thyroid carcinomas was 8.3 (range, 0.1-18) 
mm, but there were no lymph node metastases. Of 15 patients 
with normal basal calcitonin levels, 10 had medullary thyroid 
carcinoma, though two tested negative with the pentagastrin-
stimulated calcitonin assay. Five of six patients with normal 
preoperative ultrasonographic examinations had medullary 
thyroid carcinoma. Three (14%) of the patients were prescribed 
long-term calcium and vitamin D supplementation. After a 
median follow-up of 49 (range, 13-128) months, no patient had 
recurrence of medullary thyroid carcinoma.
	 Conclusions	 Genetic testing has replaced conventional biochemical and 
radiological modalities to identifying multiple endocrine 
neoplasia 2A carriers, in order to offer them prophylactic 
thyroidectomy. Chinese multiple endocrine neoplasia 2A 
patients with codon 634 mutation seem to have less aggressive 
forms of medullary thyroid carcinoma, for whom prophylactic 
thyroidectomy can be considered at the age of 8 years.
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	 目的	 檢討遺傳檢測對多發性內分泌腫瘤2A型患者的影響。
	 設計	 回顧研究。
	 安排	 香港一所大學教學醫院。
	 患者	 本研究對象為接受RET原致癌基因檢查而呈陽性反應
的22位多發性內分泌腫瘤2A型患者，他們來自八個家
庭，並已接受預防性全甲狀腺切除術。所有患者的基
因突變位置都在exon 11的codon 634上。19位術前接
受血降鈣素濃度測試中，12位有正常濃度的患者進行
五肽胃泌素激發測試。另為17位患者進行術前甲狀腺
超聲波檢查。
	 結果	 13位女性及9位男性患者的年齡中位數為25.1（介
乎6.1至71.9）歲。組織病理學顯示17人（77%）有
甲狀腺髓質癌，其餘4人（18%）有C細胞增生，另
1人（5%）屬正常；這5位是22位病人中最年青的	
（介乎6至9歲）。甲狀腺髓質癌患者中，年紀最小
為9歲；髓質癌的大小中位數為8.3 mm（介乎0.1至
18 mm），沒有出現淋巴結轉移。15位有正常血降
鈣素濃度的患者中，10位有甲狀腺髓質癌，縱然2位
的五肽胃泌素激發測試結果呈陰性。6位甲狀腺超聲
波檢查屬正常的病人中，5位有甲狀腺髓質癌。3位	
（14%）病人要長期服食鈣及維他命D補充劑。中位
數為49個月（介乎13至128個月）的隨訪期內，沒有
病人出現甲狀腺髓質復發。
	 結論	 為了讓多發性內分泌腫瘤2A型的患者進行預防性甲狀
腺切除術，遺傳檢測已取代傳統的生化及放射性檢查
方法。基因突變位置為codon 634的華藉患者，似乎
其多發性內分泌腫瘤都屬非惡性的，這種情況下，可
考慮在當患者8歲時施行預防性甲狀腺切除術。
遺傳檢測後為多發性內分泌腫瘤2A型的華籍
患者進行預防性甲狀腺切除術
availability of accurate genetic testing, prophylactic 
thyroidectomy can now be offered to all asymptomatic 
RET proto-oncogene carriers.5,8-10 Furthermore, with 
a better understanding of the genotype-phenotype 
correlation, for ‘high-risk’ carriers with codon 611, 
618, 620, or 634 mutations, it is now recommended 
that the operation should be offered as early as the 
age of 5 years.8,11 This advice was based on the fact 
that invasive MTC rarely developed earlier, but the 
recommendation provoked controversy because of 
the increased potential for surgical complications, 
parental concerns, and problems related to long-
term drug compliance.12,13
 Clinicopathological features of ethnic 
Chinese patients with MEN2A syndrome have 
been reported, but the impact of genetic testing 
and the recommendation for the optimal timing 
of prophylactic thyroidectomy have not been 
addressed.14,15
 The present study aimed at reviewing our 
experience of prophylactic thyroidectomy in 
asymptomatic MEN2A carriers after the introduction 
of genetic testing for the RET proto-oncogene, and 
to make recommendations on the optimal age for 
prophylactic thyroidectomy for our Chinese MEN2A 
patients.
Methods
Subjects
Since 2005, a territory-wide registry for patients with 
hereditary endocrinopathy has been established at 
our institution. Patients from families with suspected 
or documented MEN2 syndrome were managed 
by a multidisciplinary team, including endocrine 
surgeons, endocrinologists, radiologists, endocrine 
pathologists, and clinical oncologists. All the patients 
were followed up in the special clinic at our institution 
and genetic testing was performed in our research 
laboratory. To date, our registry has identified a 
total of eight MEN2A families. Molecular testing for 
the RET germline mutation was performed in 79 at-
risk or affected individuals from these families, after 
they had received genetic counselling; and 40 were 
confirmed to have a germline mutation in the RET 
proto-oncogene. Thyroidectomy was performed 
on a prophylactic basis for 22 genetic carriers who 
were completely asymptomatic and had no clinical 
evidence of MTC. They included 13 women and nine 
men. At the time of surgery, their median age was 25.1 
years (range, 6.1-71.9) years.
Genetic	testing
All patients and/or their legal guardians gave written 
consent, in accordance with the requirements of our 
institutional ethics committee. Blood samples were 
obtained from at-risk family members by peripheral 
veni-puncture. Genomic DNA was prepared from 
peripheral blood leukocytes by standard procedures, 
and RET mutations were screened for by restriction 
enzyme digestion and/or direct sequencing, as 
described previously.14
Preoperative	evaluation	and	surgery
Before surgery, all confirmed RET mutation carriers 
were advised to undergo a complete physical 
examination, and measurement of basal and stimulated 
plasma calcitonin, as well as serum-adjusted calcium 
and parathyroid hormone levels. At least two samples 
of 24-hour urinary fractionated catecholamines were 
assayed for patients older than 16 years to rule out 
a concomitant phaeochromocytoma. Before the 
operation, ultrasonography (USG) of the thyroid 
gland was also recommended for all confirmed 
RET carriers. For those with biochemical or imaging 
evidence of MTC, in addition to ‘prophylactic’ total 
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thyroidectomy, a unilateral central compartment 
(level VI) neck dissection was also performed.
Follow-up
All patients received lifelong thyroxine replacement 
after surgical treatment and were followed up 
regularly in our special clinic. Follow-up visits were 
arranged at 3-monthly interval in the first 2 years, 6 
monthly for the subsequent 3 years, and annually 
thereafter. Clinical examinations, basal plasma 
calcitonin, serum calcium and thyroid function tests 
were performed during follow-up visits. A stimulated 
calcitonin assay was selectively repeated for those 
with abnormal findings before surgical treatment. 
Cervical USG was performed annually to look for 
potential local/regional recurrence. Patients with 
undetectable calcitonin levels and normal USG 
findings were regarded as disease-free. Postoperative 
hypoparathyroidism was regarded as permanent if 
calcium and/or vitamin D analogues were required 
to maintain normocalcaemia in the presence of 
subnormal or undetectable parathyroid hormone 
Patient 
No.
Age at 
operation 
(years)
RET 
mutation
Basal 
calcitonin
(pmol/L)†
Peak 
calcitonin
(pmol/L)
Positive 
SCT 
response
USG 
nodule
Histology Lymph 
node
metastasis
Calcium 
supplement
Follow-up 
period 
(months)
1 6.1 C634W 1.8 1.7 No Yes CCH No No 14
2 6.3 C634Y 1.6 1.8 No Yes CCH 0/2 Yes 13
3 7.1 C634Y 0.0 0.36 No Yes CCH 0/4 Yes 13
4 8.6 C634W 0.38 0.38 No Yes Normal No No 13
5 8.9 C634Y 1.1 1.5 No No CCH 0/2 No 13
6 8.6 C634R 3.1 35.0 Yes No MTC 0.1 mm No No 49
7 10.7 C634Y 4.1 4.6 No - MTC 3.4 mm No Yes 13
8 12.3 C634Y 1.2 2.9 No No MTC 1.8 mm 0/3 No 15
9 11.9 C634Y - - - Yes MTC 5 mm No No 50
10 18.4 C634R 8.4 - - - MTC 12 mm 0/1 No 88
11 20.1 C634Y 0.44 6.5 Yes No MTC 15 mm No No 50
12 25.4 C634Y 1.6 - - No MTC in-situ 0/5 No 14
13 28.0 C634G 0.5 44.0 Yes No MTC 0.1 mm No Yes 53
14 32.1 C634G 6.5 109.0 Yes Yes MTC 5 mm 0/3 Yes 101
15 33.1 C634G 1.1 53.0 Yes Yes MTC 3 mm 0/2 Yes 52
16 34.0 C634Y 122.0 3900.0 Yes - MTC 15 mm No No 48
17 34.8 C634Y - - - - MTC 15 mm No No 128
18 41.0 C634R 4.0 72.0 Yes Yes MTC 4 mm No Yes 118
19 41.9 C634W - - - Yes MTC 8 mm 0/17 No 45
20 41.4 C634Y 4.0 - - - MTC 18 mm No Yes 56
21 50.7 C634Y 693.0 930.0 No Yes MTC 10 mm 0/3 No 57
22 71.9 C634R 4.9 - - Yes MTC 8 mm 0/1 No 83
TABLE.  The clinical, biochemical, and molecular features of the 22 asymptomatic multiple endocrine neoplasia type 2A patients who underwent 
prophylactic thyroidectomy*
* SCT denotes stimulated calcitonin test, USG ultrasonography, CCH C-cell hyperplasia, and MTC medullary thyroid carcinoma
† Normal level: <6.0 pmol/L
levels of more than 12 months after the operation.
Results
The Table shows the clinical, biochemical, and 
molecular features of the 22 RET proto-oncogene 
carriers who underwent prophylactic thyroidectomy 
based on positive genetic testing. All the RET mutations 
were located at codon 634. The specific identified RET 
mutations were as follows: C634Y (12 patients; 55%), 
C634R (4 patients; 18%), C634W (3 patients; 14%), 
and C634G (3 patients; 14%). Three (14%) patients 
were identified to have had phaeochromocytomas, 
and adrenalectomy was performed 3.8 years, 7 
months, and 3 months before their prophylactic 
total thyroidectomy. One of these three patients	
had a malignant phaeochromocytoma extending to 
the right atrium and was previously reported.16 Two 
patients underwent concomitant parathyroidectomy 
at the time of prophylactic thyroidectomy because 
of hypercalcaemia and parathyroid hyperplasia. 
One had a subtotal parathyroidectomy, while the 
other had a total parathyroidectomy and forearm 
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reimplantation.
Laboratory	and	ultrasonographic	findings
Nineteen patients had preoperative plasma basal 
calcitonin measured, of whom 15 had normal levels. 
All four patients with an elevated basal calcitonin 
level had MTC, while 10 (67%) of 15 with normal basal 
calcitonin levels also had MTC. Five (33%) of the 15 
patients with normal calcitonin levels had a positive 
calcium-pentagastrin test and an invasive MTC, 
whilst among the remaining seven with normal basal 
calcitonin level and negative calcium-pentagastrin test 
results, three had MTC on histological examination. 
Ultrasonography of the thyroid gland was performed 
in 17 patients. Five (83%) of six patients with a normal 
USG examination subsequently turned out to have 
MTC, as did seven of the 11 with one or more thyroid 
nodules detected preoperatively.
Thyroid	gland	pathology
Histological examination of the resected thyroid 
gland showed normal pathology in one (5%), C-
cell hyperplasia in four (18%), and MTC in 17 (77%) 
patients. Twelve (55%) patients had concomitant 
C-cell hyperplasia associated with the invasive 
carcinoma. C-cell hyperplasia or a normal thyroid 
gland without invasive MTC was encountered in 
the five youngest patients, with a median age of 7.1 
(range, 6.1-8.9) years. The youngest patient with MTC 
identified was 8.6 years old. The mean MTC tumour 
size on histological section was 8.3 mm (range, 0.1-18 
mm). Central lymph node dissection was performed 
in 11 (50%) of the 22 patients but none was found to 
have metastasis.
Surgical	outcome	and	follow-up	data
Postoperative laryngoscopic examination did 
not reveal any vocal cord paralysis. Eight patients 
developed postoperative hypocalcaemia for which 
both oral calcium and vitamin D supplementation 
was given, in three (14%) of whom the supplements 
became permanent. During a median follow-up of 
49 (range, 13-128) months, phaeochromocytoma 
was diagnosed in five of the patients through 
urinary screening of fractionated catecholamines, 
and after localisation with imaging they underwent 
adrenalectomy. In addition to the three patients 
who presented with phaeochromocytoma as 
their initial manifestation, five others developed 
phaeochromocytoma later during the course of their 
disease. At the time of analysis, two (9%) additional 
patients had mild hyperparathyroidism and were 
being managed expectantly. At 1-year follow-up, one 
paediatric patient had fluctuating thyroid function 
test results, despite good thyroxine compliance 
with replacement. After a median follow-up of 49 
months, no patient had any clinical, biochemical, or 
ultrasonographic evidence of MTC recurrence.
Discussion
Invasive MTC invariably develops in all patients with 
MEN2A. Since these tumours tend to metastasise 
early and are both chemo- as well as radio-resistant, 
early prophylactic surgery remains the only curative 
option.17 Graze et al18 showed that selection of affected 
kindred for prophylactic thyroidectomy through 
identification by calcitonin testing alone resulted in 
discovery of primary tumours of smaller size (0.2 cm 
vs 0.8 cm), fewer bilateral tumours (13% vs 100%), 
and fewer patients with lymph node metastases 
(0% vs 58%). With recent introduction of RET proto-
oncogene testing for the accurate identification of 
gene carriers, prophylactic thyroidectomy can be 
offered to asymptomatic affected individuals at the 
stage of pre-malignant C-cell hyperplasia before the 
histological occurrence of invasive MTC.5,8-10
 Our study confirmed that neither traditional 
biochemical tests with pentagastrin-stimulated 
calcitonin assay nor radiological imaging with USG 
could reliably predict the occurrence of invasive 
MTC. Two thirds (10/15) of the patients with normal 
preoperative basal calcitonin levels had MTC on final 
histology. Although the accuracy of the calcitonin 
assay improved with pentagastrin stimulation, three 
(20%) of the 15 patients with normal results harboured 
MTC in their thyroidectomy specimens. Preoperative 
USG imaging to identify invasive MTC was also 
inaccurate. Five (83%) of six patients with normal 
USG had MTC histologically. Even when combined 
with the pentagastrin-stimulated calcitonin assay, 
the false-negative rate remained at 50%, of which the 
finding was consistent with results reported from 
previous studies.19-21
 Although the role of RET proto-oncogene 
genetic testing to facilitate the identification of gene 
carriers for prophylactic surgery is not in dispute, 
the most appropriate timing for the operation 
remains controversial. Ideally it should be before 
the development of invasive MTC (at the stage of 
pre-malignant C-cell hyperplasia) and lymph node 
metastasis. Too early or overly aggressive surgical 
treatment, however, could be associated with 
an increased surgical morbidity and the issue of 
long-term drug compliance.17,22 A recent territory-
wide multi-centre study reported by Bergenfelz 
et al23 highlighted these issues. They reported a 
3.9% rate of vocal cord paresis, and 4.4% rate of 
hypocalcaemia for which the patients were receiving 
calcium and/or vitamin D supplements at 6 months. 
Also in a recent review of 41 MEN2A patients aged 
less than 25 years who underwent thyroidectomy, 
29% had permanent hypoparathyroidism.13 In our 
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study, although none of the subjects suffered from 
postoperative vocal cord paresis, three (14%) of 22 
had permanent hypocalcaemia, two of whom were 
among the youngest patients (<8 years). Further 
improvement in outcomes in terms of decreased 
incidence of hypocalcaemia in this growing age-
group would be of benefit for patients undergoing 
prophylactic thyroidectomy. In terms of long-term 
drug administration and compliance, two of the nine 
patients below the age of 18 years had fluctuating 
thyroid function test results on follow-up, mostly with 
persistently elevated thyroid-stimulating hormone 
levels. In this age-group, the changing requirement 
of thyroxine during growth and development, as well 
as long-term compliance with thyroxine replacement, 
also needs further evaluation.
 The application of ‘codon-directed’ guidelines 
for management of MEN2A patients apparently 
originated from the West. The objective of the present 
study was to identify any potential differences with 
respect to this genetic disease in our population. 
Based on the international consensus statement in 
2001,11 all our 22 patients (with codon 634 mutation) 
belonged to the ‘high-risk’ group, for which surgery 
was recommended before the age of 5 years in order 
to avoid the occurrence of invasive MTC. In our series, 
the earliest age for positive identification of MTC 
development in our MEN2A patients was 8 years, while 
four other younger patients were confirmed to have 
either normal histology or C-cell hyperplasia. Based 
on our experience, and taking into consideration 
the problems emanating from surgery in very 
young patients as well as the need to take long-term 
thyroxine, it might be worth considering prophylactic 
thyroidectomy at the age of 8 rather than 5 years. In 
addition, despite the ‘prophylactic’ operation being 
performed in patients up to 71 years old and a tumour 
size of 1.8 cm (owing to genetic study at a delayed 
stage), none of our patients were identified to have 
lymph node metastases and all have remained free of 
disease till their latest follow-up. Our findings should 
be interpreted cautiously however, as the number of 
patients studied was relatively small, whilst in other 
populations undergoing prophylactic thyroidectomy, 
invasive MTC has been reported in patients as young 
as 17 months.24,25 In summary, although our ethnic 
Chinese MEN2A patients with codon 634 mutation 
appeared to be suffering from a less aggressive form 
of MTC, a prospective study involving a larger number 
of ethnic Chinese patients is required.
Conclusions
Genetic RET proto-oncogene testing has replaced 
traditional biochemical tests and imaging to facilitate 
decisions about prophylactic thyroidectomy in MEN2A 
families. To prevent the development of invasive 
MTC, our experience in the management of local 
MEN2A patients suggests resorting to prophylactic 
thyroidectomy for these children possibly at the 
age of 8 years or younger. The risk of permanent 
hypoparathyroidism and the issue of early long-term 
thyroid function and replacement therapy remain a 
concern in this group of young children.
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